Promoter Acquires 60,000 Shares in Goldline Pharmaceutical Limited; Holding Reaches 29.27%
Swapan Khandelwal, a Promoter and Whole Time Director of Goldline Pharmaceutical Limited, has increased his holding in the company through the open market purchase of equity shares. The acquisition was completed on June 22, 2026.The transaction details indicate that Mr. Swapan Khandelwal acquired 60,000 equity shares. This purchase directly contributed to an increase in his shareholding percentage in Goldline Pharmaceutical Limited.
Prior to the acquisition, Mr. Khandelwal held 2,749,988 shares, representing 28.65% of the total issued and paid up share capital. Following the open market purchase, his holding increased to 2,809,988 shares, which translates to a 29.27% stake in the company.
The following table summarizes the details of Mr. Khandelwal's acquisition:
| Metric | Before Acquisition | Transaction Details | After Acquisition |
|---|---|---|---|
| Shares Held (Voting Rights) | 2,749,988 | Acquired 60,000 shares | 2,809,988 |
| Percentage of Total Share Capital | 28.65% | Mode: Open Market Purchase | 29.27% |
The company’s total equity share capital remained at 9,600,000 Equity Shares both before and after the acquisition.
Stock Price Movement
Goldline Pharmaceutical Ltd. shares settled on Tuesday at ₹46.57, climbing a solid 8.03% in post-market trading. The stock experienced intraday volatility, testing a low of ₹42.84 before reaching an intraday high of ₹47.95.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.